Quanterix Corporation
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Quanterix Corporation operates as a pioneering life sciences organization, specializing in the development and global commercialization of advanced digital immunoassay platforms designed to propel precision health initiatives for both research and diagnostic applications across North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company showcases its flagship Simoa® (Single Molecule Array) technology through instruments like the HD-X Analyzer, an automated system for highly sensitive protein biomarker detection, and the SR-X Biomarker Detection System, which broadens ultra-sensitive detection capabilities to include nucleic acids. Additionally, its SP-X Imaging and Analysis System utilizes Simoa planar array technology for comprehensive multiplex chemiluminescent immunoassay measurements. Beyond its core instrumentation, Quanterix provides a diverse array of complementary products, including various assay kits—such as those for dry blood extraction, LDT assays, and custom homebrew development—along with essential reagents and other consumables. The company further extends its offerings through specialized contract research services, encompassing sample analysis, customized assay creation, and Lucent Diagnostics LDT testing, all facilitated by its CLIA-certified Simoa Accelerator Laboratory. Quanterix strategically focuses its efforts across critical therapeutic domains, including neurology, with an emphasis on neurodegeneration, neuroinflammation, and Alzheimer's disease biomarkers; oncology, supporting early cancer detection and liquid biopsies; immunology; cardiology; and infectious diseases. The company engages its diverse client base—comprising academic and governmental research institutions, pharmaceutical and biotechnology firms, and contract research organizations—through a dedicated direct sales force, robust support networks, and a wide array of distributors. Founded in 2007, Quanterix Corporation maintains its corporate headquarters in Billerica, Massachusetts.
Quanterix To Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Quanterix Announces Planned Transition of Chief Financial Officer
Quanterix Corporation (QTRX) Q1 2026 Earnings Call Transcript
Quanterix Corporation (QTRX) Reports Q1 Loss, Lags Revenue Estimates
Quanterix Releases Financial Results for the First Quarter of 2026
Lucent Diagnostics Announces Collaboration with Tempus to Integrate Blood-Based Alzheimer's Biomarker Testing into Clinical Workflows
Quanterix To Report First Quarter 2026 Financial Results on May 6, 2026
AidaBREAST™ Multi-Omic Assay Demonstrates Spatial Proteomics for Clinical Oncology
Quanterix Debuts Content Innovation Engine at AACR 2026
Aberdeen Group plc Trims Stock Holdings in Quanterix Corporation $QTRX
Quanterix Corporation Announces Date of 2026 Annual Meeting
Analyzing Quanterix (NASDAQ:QTRX) & IM Cannabis (NASDAQ:IMCC)
Quanterix (NASDAQ:QTRX) vs. TREES (OTCMKTS:CANN) Head-To-Head Review
Quanterix Corporation (QTRX) Q4 2025 Earnings Call Transcript
Quanterix Corporation (QTRX) Reports Q4 Loss, Beats Revenue Estimates
Quanterix Releases Financial Results for the Fourth Quarter and Full Year 2025
Lucent Diagnostics and Life Line Screening Partner to Bring Advanced Blood-Based Diagnostics to Communities Nationwide
Quanterix to Participate in Upcoming Investor Conferences
Quanterix To Report Fourth Quarter and Full Year 2025 Financial Results on March 2, 2026